Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines administered as fourth-dose boosters after two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicenter, blinded phase 2, randomized trial

SARS-CoV-2 anti-spike protein IgG concentration, ELU/mL Day 28 after the third dose 23,325 (20,030–27,162); 66 25,317 (20,996–30,528); 66 20,502 (16,473–25,517); 35 21,980 (16,476–29,324); 33 26,982 (22,056–33,008); 31 29,161 (23,093–36,823); 33 Day 0 of fourth dose 3049 (2550–3646); 66 3469 (2730–4407); 66 2532 (1974–3247); 35 2571 (1874–3527); 3. 4 3761 (2959–4780); 31 4769 (3421–6648); 32 Day 14 after the fourth dose 37,460 (31,996–43,857); Sixty-five 54,936 (46,826–64,452); 67 33,316 (26,942–41,198); 35 52,080 (41,163–65,894); 3. 4 42,949 (34,148–54,019); 30 58,043 (46,693–72,150); 33 Fold change (day 14 after the fourth dose) against day 28 after the third dose) 1 59 (1 41–1 78); Sixty-five 2 19 (1 90–2 52); 66 1 62 (1 35–1 95); 35 2 41 (1 90–3 05); 33 1 54 (1 35–1 76); 30 1 99 (1 71–2 31); 33 Fold change (day 14 after the fourth dose) against day 0 of the fourth dose) 12 19 (10 37–14 32); Sixty-five 15 90 (12 92–19 58); 66 13 16 (10 24–16 91); 35 20 26 (15 09–27 21); 3. 4 11 14 (9 21–13 47); 30 12 30 (9 39–16 11); 32 Cellular response (wild type), stain-forming cells per 106 PBMC

*

For logistical reasons, only 50% of study sites collected cellular immunology samples (proximity to an outside laboratory) in the main COV-BOOST study; cellular immunology samples after the fourth dose were collected in the immunology cohort.